findmyKOL
Clinical trialNCT03192306CompletedPhase 2Interventional

Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for Episodic Treatment of Cold Sores

SponsorTopical RemedyEnrollment451Recurrent Herpes Labialis
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Optimal Research

    Huntsville, Alabama, United States

  • Optimal Research

    San Diego, California, United States

  • Optimal Research

    Melbourne, Florida, United States

  • Optimal Research

    Peoria, Illinois, United States

  • Optimal Research

    Rockville, Maryland, United States

  • Optimal Research

    Austin, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
5 Jul 2017
Primary completion
11 Dec 2017
Completion
2 Apr 2018
Last update posted
12 Sept 2018
Registered enrollment
451
Registry id
NCT03192306

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.